Cargando…
Rationale for the Development of a Pentavalent Meningococcal Vaccine: A US-Focused Review
While invasive meningococcal disease (IMD) is uncommon, it can result in serious sequelae and even death. In 2018 in the United States, the incidence of IMD per 100,000 people was 0.03 among adolescents 11−15 years of age, 0.10 among persons 16−23 years of age, and 0.83 among infants < 1 year of...
Autores principales: | Marshall, Gary S., Fergie, Jaime, Presa, Jessica, Peyrani, Paula |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8969818/ https://www.ncbi.nlm.nih.gov/pubmed/35357651 http://dx.doi.org/10.1007/s40121-022-00609-9 |
Ejemplares similares
-
1146. Cost-effectiveness of the Pentavalent Meningococcal Vaccine (MenABCWY): A steady-state cohort modelling approach
por: Schley, Katharina, et al.
Publicado: (2023) -
1638. Development of a Model to Estimate Persistence of hSBA Titers Over Time Following a Primary Series and Booster Dose of the Pentavalent Meningococcal MenABCWY Vaccine
por: Cai, Bing, et al.
Publicado: (2023) -
Meningococcal disease in adolescents and young adults: a review of the rationale for prevention through vaccination
por: Burman, Cynthia, et al.
Publicado: (2018) -
3. A Review of the Clinical Development of MenACWY-TT, a Quadrivalent Meningococcal Vaccine Conjugated to Tetanus Toxoid, in Adolescents
por: Peyrani, Paula, et al.
Publicado: (2020) -
Evaluation of Critical Quality Attributes of a Pentavalent (A, C, Y, W, X) Meningococcal Conjugate Vaccine for Global Use
por: Bolgiano, Barbara, et al.
Publicado: (2021)